4-(4-氯苯基)-5-甲基噻唑-2-胺 | 82632-77-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(4-氯苯基)-5-甲基噻唑-2-胺
• 中文别名: 4-(4-氯苯基)-5-甲基-噻唑-2-胺
• 英文名称: 2-amino-4-(4’-chlorophenyl)-5-methyl-1,3-thiazole
• 英文别名: 2-amino-4-(p-chlorophenyl)-5-methylthiazole；4-(4-chlorophenyl)-5-methylthiazol-2-amine；SCRC2941-18；4-(4-chloro-phenyl)-5-methyl-thiazol-2-ylamine；4-(4-chlorophenyl)-5-methyl-1,3-thiazole-2-amine；4-(4-chlorophenyl)-5-methyl-1,3-thiazol-2-amine
• CAS: 82632-77-7
• 化学式: C₁₀H₉ClN₂S
• mdl: MFCD00731832
• 分子量: 224.714
• InChiKey: IEJGVSUOFMBPJU-UHFFFAOYSA-N

物化性质

• 熔点：
  144-145℃ (hexane ethyl acetate )
• 沸点：
  376.6±27.0 °C(Predicted)
• 密度：
  1.338±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放于惰性气体中，避免接触空气。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(4-Chloro-phenyl)-5-methyl-thiazol-2-ylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Chloro-phenyl)-5-methyl-thiazol-2-ylamine
CAS number: 82632-77-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H9ClN2S
Molecular weight: 224.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-氯苯基)-5-甲基噻唑-2-胺 在 tetrafluoroboric acid 、 sodium nitrite 作用下， 生成 4-(4-chloro-phenyl)-5-methyl-thiazole-2-diazonium; tetrafluoroborate
  参考文献：
  名称：

  Gruenert,C. et al., Zeitschrift fur Chemie, 1970, vol. 10, p. 116

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯-alpha-乙基苄醇 在 manganese(IV) oxide 、 碘 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 生成 4-(4-氯苯基)-5-甲基噻唑-2-胺
  参考文献：
  名称：

  Sulfonylated aminothiazoles as new small molecule inhibitors of protein phosphatases

  摘要：

  Based on a previously identified lead structure, SC-alpha alpha delta9, we have developed a versatile new chemical scaffold that can be readily modified to generate libraries of both Tyr and dual specificity phosphatase inhibitors with reduced molecular weight and lipophilicity. The most potent analogue identified to dare, aminothiazole 8z, inhibits the dual specificity phosphatase Cdc25B with a K-i of 4.6 +/- 0.4 muM and a Hill coefficient of 2. (C) 2001 Elsevier Science Ltd. Ail rights reserved.

  DOI：

  10.1016/s0960-894x(00)00658-2

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Florjancic S. Alan

  公开号：US20080058335A1

  公开（公告）日：2008-03-06

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , and L 1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1a , R 2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1 ，R 2 ，R 3 和L 1 在规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1a ，R 2a 和(Rx)n如规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• Synthesis, activity, and docking study of phenylthiazole acids as potential agonists of PPARγ
  作者：Liang Ma、Taijin Wang、Min Shi、Haoyu Ye

  DOI：10.2147/dddt.s106406

  日期：——

  glucose and lipid homeostasis, and PPARγ ligands possess therapeutic potential in these as well as other areas. In this study, a series of phenylthiazole acids have been synthesized and evaluated for agonistic activity by a convenient fluorescence polarization-based PPARγ ligand screening assay. Compound 4t, as a potential PPARγ agonist with half maximal effective concentration (EC50) 0.75±0.20 μM, exhibited

  过氧化物酶体增殖物激活受体γ（PPARγ）是配体介导的转录因子，在葡萄糖和脂质体内平衡中起关键作用，PPARγ配体在这些以及其他领域具有治疗潜力。在这项研究中，已经合成了一系列苯基噻唑酸，并通过方便的基于荧光偏振的PPARγ配体筛选测定法评估了其激动活性。化合物4t作为潜在的PPARγ激动剂，最大有效浓度（EC50）为一半，为0.75±0.20μM，其体外效力可与0.83±0.14μM的阳性对照罗格列酮媲美。分子对接和分子动力学模拟表明，苯基噻唑酸4t与PPARγ复合物活性位点的氨基酸残基稳定地相互作用，
• [EN] NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QUE LIGANDS DE RÉCEPTEUR DE CANNABINOÏDE ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2009067613A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物，式(I)。其中R1、R2、R3、R4和L1在规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物，式(II)。其中R1a、R2a、Rx和n如规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• Citric Acid-catalyzed Synthesis of 2,4-Disubstituted Thiazoles from Ketones via C-Br, C-S, and C-N Bond Formations in One Pot: A Green Approach
  作者：Trivikram Reddy Gundala、Kumar Godugu、Chinna Gangi Reddy Nallagondu

  DOI：10.1002/jccs.201700200

  日期：2017.12

  protocol has been developed for the synthesis of 2,4‐disubstituted thiazoles via C–Br, C–S, and, C–N bond formations in a single step from readily available ketones, N‐bromosuccinimide (NBS), and thiourea catalyzed by citric acid in a mixture of ethanol and water (3:1) under reflux conditions. This method has the advantages of freedom from the isolation of lachrymatory α‐bromoketones, ease of carrying

  已开发出一种改进的，更环保的方案，可通过一步一步从现成的酮类N-溴代琥珀酰亚胺（NBS），C-Br，C-S和C-N键的形成中合成2,4-二取代的噻唑，在回流条件下，柠檬酸在乙醇和水（3：1）的混合物中由柠檬酸催化硫脲。该方法的优点是无需分离催泪性α-溴代酮，易于操作，反应曲线更干净，底物范围宽，无需色谱纯化和适合大规模合成。
• THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE
  申请人：Suzuki Masaki

  公开号：US20150307477A1

  公开（公告）日：2015-10-29

  Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.

  本文描述了利用调节纹状体富集的酪氨酸磷酸酶（STEP）的化合物来治疗疾病的方法。示例疾病包括精神分裂症和认知缺陷。

表征谱图